Wacker Chemie

A precipitous step deeper into the CDMO business

23/11/20 -"Wacker's Biosolutions business has become a partner of choice for German mRNA player CureVac. Currently, the technology transfer for the production of CureVac's COVID-19 vaccine candidate is being ..."

PDF page sample
Pages
47
Language
English
Published on
23/11/20
Download
You may also be interested by these reports :
28/10/25
The Q3 25 trading statement of the group aligned with expectations, showing a topline consistent with H1/Q2 25 results. We anticipate no significant ...
28/10/25
The change in the target price is due to a change in the analyst covering the stock, complemented by the usage of systematic intrinsic and peer-based ...
24/10/25
The change in the target price is due to a change in the analyst covering the stock, complemented by the usage of systematic intrinsic and peer-based ...
22/10/25
Akzo Nobel’s Q3 2025 results were broadly in line, with moderate growth in Decorative Paints supported by China and Latin America, partly offset by ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO